PharmAust Limited (PAA.AX)

0.2300 +0.0150 (+6.98%) At close: 04:10PM AEDT

PharmAust Limited

96-100 Albert Road
Level 4
Melbourne, VIC 3205
Australia
61 3 9692 7222
https://www.pharmaust.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Michael Thurn Ph.D.	MD, CEO & Director	316.88k	N/A	N/A
Mr. John Clark	Chief Operating Officer	74.67k	N/A	N/A
Dr. Nicky Wallis	Chief Scientific Officer	26.16k	N/A	N/A
Ms. Fiona Milner	General Manager of Epichem Pty Ltd	26.69k	N/A	N/A
Dr. Gary Pitt	Head of Chemistry	N/A	N/A	N/A
Dr. James Rixson	Head of Production	N/A	N/A	N/A
Dr. Herbert Brinkman	Head of Manufacturing	N/A	N/A	N/A
Mr. Stefan Ross	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

PharmAust Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. PharmAust Limited was incorporated in 2000 and is based in Melbourne, Australia.

Corporate governance

PharmAust Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.